REVIEW ARTICLE
Advances from targeted therapy for non-metastatic HER2-positive inflammatory breast cancer
Jessica A. Steadman,
Tina J. Hieken,
Jessica A. Steadman
Department of Surgery, Division of Breast and Melanoma Surgical Oncology, Mayo Clinic, Rochester, Minnesota, USA
Search for more papers by this authorCorresponding Author
Tina J. Hieken
Department of Surgery, Division of Breast and Melanoma Surgical Oncology, Mayo Clinic, Rochester, Minnesota, USA
Correspondence Tina J. Hieken, Department of Surgery, Division of Breast and Melanoma Surgical Oncology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA.
Email: [email protected]; Twitter: @TJH0828
Search for more papers by this authorJessica A. Steadman,
Tina J. Hieken,
Jessica A. Steadman
Department of Surgery, Division of Breast and Melanoma Surgical Oncology, Mayo Clinic, Rochester, Minnesota, USA
Search for more papers by this authorCorresponding Author
Tina J. Hieken
Department of Surgery, Division of Breast and Melanoma Surgical Oncology, Mayo Clinic, Rochester, Minnesota, USA
Correspondence Tina J. Hieken, Department of Surgery, Division of Breast and Melanoma Surgical Oncology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA.
Email: [email protected]; Twitter: @TJH0828
Search for more papers by this authorAbstract
Among inflammatory breast cancer (IBC) patients, over one-third have HER2-overexpressing (HER2+) tumors. Pathologic complete response (pCR) rates to neoadjuvant targeted and chemotherapy for patients with HER2+ non-metastatic IBC now apporach 60% and favorable long-term survival rates are being reported for those with a pCR. Immune mechanisms contributing to this phenomenon include antibody-mediated immune activation and induction of memory T-cell reponses which may explain the sustained antitumor response seen after discontinuation of targeted therapies.
Open Research
DATA AVAILABILITY STATEMENT
All data used for this review article are from literature referenced in the text and publicly available.
REFERENCES
- 1Dawood S, Merajver SD, Viens P, et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol. 2011; 22(3): 515-523.
- 2Anderson WF, Schairer C, Chen BE, Hance KW, Levine PH. Epidemiology of inflammatory breast cancer (IBC). Breast Dis. 2005; 22: 9-23.
- 3Hieken TJ, Murphy BL, Boughey JC, Degnim AC, Glazebrook KN, Hoskin TL. Influence of biologic subtype of inflammatory breast cancer on response to neoadjuvant therapy and cancer outcomes. Clin Breast Cancer. 2018; 18(4): e501-e506.
- 4Kupstas AR, Hoskin TL, Day CN, Boughey JC, Habermann EB, Hieken TJ. Biological subtype, treatment response and outcomes in inflammatory breast cancer using data from the National Cancer Database. Br J Surg. 2020; 107(8): 1033-1041.
- 5Fouad TM, Kogawa T, Liu DD, et al. Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Res Treat. 2015; 152(2): 407-416.
- 6Bravo MJ, Burgos-Molina AM, García-Aranda M, Redondo M, Téllez T. Unlocking new avenues in breast cancer treatment: the synergy of kinase inhibitors and immunotherapy. Cancers. 2023; 15(23): 5499.
- 7Ryan Q, Ibrahim A, Cohen MH, et al. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist. 2008; 13(10): 1114-1119.
- 8Martin M, Holmes FA, Ejlertsen B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017; 18(12): 1688-1700.
- 9Dai MS, Feng YH, Chen SW, et al. Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens. Breast Cancer Res Treat. 2021; 189(3): 665-676.
- 10Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020; 382(7): 597-609.
- 11Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011; 365(14): 1273-1283.
- 12Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344(11): 783-792.
- 13Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol. 2014; 15(6): 640-647.
- 14Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016; 17(6): 791-800.
- 15Amiri-Kordestani L, Wedam S, Zhang L, et al. First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer. Clin Cancer Res. 2014; 20(21): 5359-5364.
- 16Margetuximab 2024. https://go.drugbank.com/drugs/DB14967
- 17Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022; 387(1): 9-20.
- 18Gradishar WJ, Moran MS, Abraham J, et al. 2024. NCCN clinical practice guidelines in oncology: breast cancer version 2. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
- 19Dawood S, Ueno NT, Valero V, et al. Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer. 2011; 117(9): 1819-1826.
- 20von Minckwitz G, Huang C-S, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019; 380(7): 617-628.
- 21Cortés J, Kim S-B, Chung W-P, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022; 386(12): 1143-1154.
- 22Hieken TJ, Boughey JC, Degnim AC, Glazebrook KN, Hoskin TL. Inflammatory breast cancer: durable breast cancer-specific survival for HER2-positive patients with a pathologic complete response to neoadjuvant therapy. Ann Surg Oncol. 2022; 29(9): 5383-5386.
- 23Pernas S, Guerriero JL, Naumenko S, et al. Early on-treatment transcriptional profiling as a tool for improving pathological response prediction in HER2-positive inflammatory breast cancer. Ther Adv Med Oncol. 2022; 14:175883592211132.
10.1177/17588359221113269 Google Scholar
- 24Ferris RL, Lenz HJ, Trotta AM, et al. Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation. Cancer Treat Rev. 2018; 63: 48-60.
- 25Musolino A, Gradishar WJ, Rugo HS, et al. Role of Fcγ receptors in HER2-targeted breast cancer therapy. J Immunother Cancer. 2022; 10(1):e003171.
- 26Chaganty BKR, Qiu S, Gest A, et al. Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion. Cancer Lett. 2018; 430: 47-56.
- 27Bianchini G, Pusztai L, Pienkowski T, et al. Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial. Ann Oncol. 2015; 26(12): 2429-2436.
- 28Musolino A, Boggiani D, Pellegrino B, et al. Role of innate and adaptive immunity in the efficacy of anti-HER2 monoclonal antibodies for HER2-positive breast cancer. Crit Rev Oncol Hematol. 2020; 149:102927.
- 29Loi S, Giobbie-Hurder A, Gombos A, et al. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. Lancet Oncol. 2019; 20(3): 371-382.
- 30Chia S, Bedard PL, Hilton J, et al. A phase Ib trial of durvalumab in combination with trastuzumab in HER2-positive metastatic breast cancer (CCTG IND.229). Oncologist. 2019; 24(11): 1439-1445.
- 31Hieken TJ, Hoskin TL. ASO author reflections: inflammatory breast cancer: durable breast cancer-specific survival for HER2-positive patients with a pathologic complete response to neoadjuvant therapy. Ann Surg Oncol. 2022; 29(suppl 3): 597-598.
- 32Leon-Ferre RA, Hieken TJ, Boughey JC. The landmark series: neoadjuvant chemotherapy for triple-negative and HER2-positive breast cancer. Ann Surg Oncol. 2021; 28(4): 2111-2119.
